For example, circulating biomarkers such as soluble PD-L1 and cytokine profiles have shown promise in predicting responses to immune checkpoint inhibitors in melanoma, highlighting the clinical relevance of immune-related gene signatures similar to those identified in our study (47). Here, CD274 is linked to melanoma.